CoChat

Prevention of Diabetes With Pioglitazone in ACT NOW

Open access

The DOI matches its Crossref record, with a small difference in title or year; 42 of the 42 references it cites were found in a registry or an index.

Abstract

We examined the metabolic characteristics that attend the development of type 2 diabetes (T2DM) in 441 impaired glucose tolerance (IGT) subjects who participated in the ACT NOW Study and had complete end-of-study metabolic measurements. Subjects were randomized to receive pioglitazone (PGZ; 45 mg/day) or placebo and were observed for a median of 2.4 years. Indices of insulin sensitivity (Matsuda index [MI]), insulin secretion (IS)/insulin resistance (IR; ΔI0–120/ΔG0–120, ΔIS rate [ISR]0–120/ΔG0–120), and β-cell function (ΔI/ΔG × MI and ΔISR/ΔG × MI) were calculated from plasma glucose, insulin, and C-peptide concentrations during oral glucose tolerance tests at baseline and study end. Diabetes developed in 45 placebo-treated vs. 15 PGZ-treated subjects (odds ratio [OR] 0.28 [95% CI 0.15–0.49]; P < 0.0001); 48% of PGZ-treated subjects reverted to normal glucose tolerance (NGT) versus 28% of placebo-treated subjects (P < 0.005). Higher final glucose tolerance status (NGT > IGT > T2DM) was associated with improvements in insulin sensitivity (OR 0.61 [95% CI 0.54–0.80]), IS (OR 0.61 [95% CI 0.50–0.75]), and β-cell function (ln IS/IR index and ln ISR/IR index) (OR 0.26 [95% CI 0.19–0.37]; all P < 0.0001). Of the factors measured, improved β-cell function was most closely associated with final glucose tolerance status.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2337/db13-0265

Cites

42 of 42 references verified0 citation errors · 0 not checkable

Statistics

Figures

FIG. 1. Change from baseline to study end in MI (top left), IS (ΔI0–120/ΔG0–120 AUC) (bottom left), IS/IR index (bottom right), and adipose tissue IR index (top right) in PGZ-treated subjects. Data are given as means ± SE. Change represents the difference between the absolute value at the study end minus baseline value. *P < 0.05 for NGT vs. IGT or T2DM; #P < 0.05 for IGT vs. T2DM using nonparametric tests.
FIG. 1. Change from baseline to study end in MI (top left), IS (ΔI0–120/ΔG0–120 AUC) (bottom left), IS/IR index (bottom right), and adipose tissue IR index (top right) in PGZ-treated subjects. Data are given as means ± SE. Change represents the difference between the absolute value at the study end minus baseline value. *P < 0.05 for NGT vs. IGT or T2DM; #P < 0.05 for IGT vs. T2DM using nonparametric tests.CC BY-NC-ND · PubMed Central
FIG. 2. Change in MI (top left), IS (ΔI0–120/ΔG0–120) (bottom left), IS/IR index (bottom right), and adipose tissue IR index (top right) in placebo-treated subjects. Data are given as means ± SE. Change represents the difference between the absolute value at the study end minus baseline value. *P < 0.05 for NGT vs. IGT or T2DM; #P < 0.05 for IGT vs. T2DM using nonparametric tests.
FIG. 2. Change in MI (top left), IS (ΔI0–120/ΔG0–120) (bottom left), IS/IR index (bottom right), and adipose tissue IR index (top right) in placebo-treated subjects. Data are given as means ± SE. Change represents the difference between the absolute value at the study end minus baseline value. *P < 0.05 for NGT vs. IGT or T2DM; #P < 0.05 for IGT vs. T2DM using nonparametric tests.CC BY-NC-ND · PubMed Central
FIG. 3. Relationship between the annual diabetes incidence rate and change in the IS/IR index in the combined PGZ-treated and placebo-treated groups. Cohort members were ordered from smallest to largest change and then divided into octiles. Means ± SEM of each octile are represented by solid circles. SEM values for diabetes incidence are not shown if they fall within the height of the solid circle.
FIG. 3. Relationship between the annual diabetes incidence rate and change in the IS/IR index in the combined PGZ-treated and placebo-treated groups. Cohort members were ordered from smallest to largest change and then divided into octiles. Means ± SEM of each octile are represented by solid circles. SEM values for diabetes incidence are not shown if they fall within the height of the solid circle.CC BY-NC-ND · PubMed Central
FIG. 4. Relationship between IS (ΔI0–120/ΔG0–120) and MI at baseline (A) and at study end (B). NGT subjects, yellow circles; IGT subjects who converted to NGT, blue triangles; IGT subjects who remained with IGT, red squares; IGT subjects who converted to T2DM, green diamonds.
FIG. 4. Relationship between IS (ΔI0–120/ΔG0–120) and MI at baseline (A) and at study end (B). NGT subjects, yellow circles; IGT subjects who converted to NGT, blue triangles; IGT subjects who remained with IGT, red squares; IGT subjects who converted to T2DM, green diamonds.CC BY-NC-ND · PubMed Central
FIG. 5. PG (top) and insulin (middle) concentrations and ISR (bottom) in PGZ-treated IGT subjects who reverted to NGT (left), remained with IGT (middle), or converted to T2DM (right). Data at baseline and at the end of PGZ treatment are shown. For comparison, data for control NGT individuals identified during the screening of participants for the ACT NOW Study are shown.
FIG. 5. PG (top) and insulin (middle) concentrations and ISR (bottom) in PGZ-treated IGT subjects who reverted to NGT (left), remained with IGT (middle), or converted to T2DM (right). Data at baseline and at the end of PGZ treatment are shown. For comparison, data for control NGT individuals identified during the screening of participants for the ACT NOW Study are shown.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 42 references

Cited by

Metadata

Authors
DeFronzo, R. A., Tripathy, D., Schwenke, D. C., Banerji, M., Bray, G. A., Buchanan, T. A., Clement, S. C., Gastaldelli, A., Henry, R. R., Kitabchi, A. E., Mudaliar, S., Ratner, R. E., Stentz, F. B., Musi, N., Reaven, P. D., & Study, F. T. A. N.
Affiliations
  • The University of Texas at San Antonio Health Science Center (US)
  • Phoenix VA Health Care System (US)
  • SUNY Downstate Health Sciences University (US)
  • Pennington Biomedical Research Center (US)
  • University of Southern California (US)
  • Georgetown University (US)
  • University of California San Diego (US)
  • University of Tennessee Health Science Center (US)
  • MedStar Health Research Institute (US)
Corresponding author
DeFronzo, Ralph A.
Venue
Diabetes
Published
2013-10-18
Volume
62
Issue
11
Pages
3920-3926
ISSN
  • 0012-1797 (ISSN-L)
  • 1939-327X
OpenAlex
W2103930636
Cited by
109
References
42
Citations by year
2026: 5 · 2025: 8 · 2024: 5 · 2023: 5 · 2022: 7 · 2021: 12 · 2020: 11 · 2019: 6 · 2018: 8 · 2017: 8 · 2016: 11 · 2015: 7 · 2014: 14 · 2013: 2
FWCI
8.91
Type
journal article
Language
en
Open access
Locations
  • Diabetes (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
Funders
  • Amgen
  • Bristol-Myers Squibb
  • Eli Lilly and Company
  • AstraZeneca
  • Sanofi
  • Gilead Sciences
  • University of Southern California
  • Intarcia Therapeutics
  • Novo Nordisk
  • National Institutes of Health (UL1TR000130)
  • Health Science Center, University of Tennessee
  • Allergan
  • National Center for Research Resources (M01-RR00221)
  • National Center for Advancing Translational Sciences
  • Daiichi Sankyo Europe
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
Keywords
pioglitazone, type 2 diabetes prevention, impaired glucose tolerance, insulin sensitivity, Matsuda index, insulin secretion, insulin resistance, beta-cell function, glucose tolerance, thiazolidinediones
MeSH terms
Pioglitazone, Blood Glucose, Diabetes Mellitus, Type 2, Female, Glucose Tolerance Test, Humans, Insulin, Insulin Resistance, Male, Middle Aged, Glucose Intolerance, Thiazolidinediones, Insulin-Secreting Cells

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.